Details of Disease

General Information of Disease (ID: DISDI0CT)

• Disease Name: Salivary gland squamous cell carcinoma
• Synonyms: squamous cell carcinoma of salivary glands; salivary gland SCC; epidermoid carcinoma of salivary gland; salivary gland epidermoid carcinoma; squamous cell carcinoma of salivary gland; salivary gland squamous cell cancer; salivary gland squamous cell carcinoma; SCC of salivary gland; saliva-secreting gland squamous cell carcinoma; squamous cell carcinoma of the salivary gland; epidermoid carcinoma of the salivary gland; SCC of the salivary gland
• Definition: A squamous cell carcinoma arising from the salivary glands. The majority of patients are in their sixth through eight decades. It usually presents as a rapidly enlarging mass, which may be painful. It usually has an aggressive clinical course.
• Disease Hierarchy:
  DISHL784: Malignant epithelial tumor of salivary glands
  DISLVGGG: Salivary gland carcinoma
  DISQVIFL: Squamous cell carcinoma
  DISQVJVA: Oral cavity squamous cell carcinoma
  DISDI0CT: Salivary gland squamous cell carcinoma
• Disease Identifiers:
  MONDO ID: MONDO_0044740
  UMLS CUI: C0279697
  MedGen ID: 83545
  Orphanet ID: 500481

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 5 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Cetuximab	DMLNCE0	Approved	Antibody	[1]
Erlotinib	DMCMBHA	Approved	Small molecular drug	[2]
Everolimus	DM8X2EH	Approved	Small molecular drug	[3]
Sirolimus	DMGW1ID	Approved	Small molecular drug	[4]
Sunitinib	DMCBJSR	Approved	Small molecular drug	[5]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Patient-derived head and neck cancer organoids allow treatment stratification and serve as a tool for biomarker validation and identification. Med. 2023 May 12;4(5):290-310.e12.
• [2] Erlotinib FDA Label
• [3] Everolimus FDA Label
• [4] Sirolimus FDA Label
• [5] Sunitinib FDA Label